metformin has been researched along with tofacitinib in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Alvey, C; Dowty, ME; Feng, B; Kaplan, I; Klamerus, KJ; Krishnaswami, S; Li, L; Shi, H; Wang, R | 1 |
Akar, ZA; Akkoc, RF; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B | 1 |
1 trial(s) available for metformin and tofacitinib
Article | Year |
---|---|
Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Topics: Administration, Oral; Adult; Area Under Curve; Belgium; Drug Interactions; Female; Healthy Volunteers; HEK293 Cells; Humans; Janus Kinase Inhibitors; Kidney Tubules; Male; Metformin; Middle Aged; Organic Cation Transporter 2; Piperidines; Pyrimidines; Pyrroles; Renal Elimination; Transfection; Young Adult | 2014 |
3 other study(ies) available for metformin and tofacitinib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.
Topics: Animals; Drug Therapy, Combination; Female; Fibrosis; Metformin; Mice; Mice, Inbred BALB C; Piperidines; Pyrimidines; Scleroderma, Systemic; Skin | 2022 |